In addition to its administration as a cardiovascular therapeutic and as a chemosensitizer together with anti-cancer drugs, verapamil is widely used in drug–drug interaction (DDI) studies and is recommended by the FDA as a moderate clinical CYP3A4 index inhibitor and as a clinical Pgp inhibitor [7]. Here, PGP is linked to cancer.